Characterization of Antibodies to Capsular Polysaccharide Antigens of Haemophilus influenzae Type b and Streptococcus pneumoniae in Human Immune Globulin Intravenous Preparations

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Diagnostic Laboratory Immunology

• Publication date

  2004-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/CDLI.11.6.1158-1164.2004PMID 15539522PMCID PMC524781
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pneumococcal vaccines

  2020cited by this paper
• Clinical and immunologic analyses of 103 patients with common variable immunodeficiency

  2004cited by this paper
• Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.

  2002cited by this paper
• Intravenous immunoglobulins: clinical experience and viral safety.

  2002influential reference
• A direct comparison of the antigen‐specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma

  2002cited by this paper
• Immunoglobulin G3 from Polyclonal Human Immunodeficiency Virus (HIV) Immune Globulin Is More Potent than Other Subclasses in Neutralizing HIV Type 1

  2001cited by this paper
• Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent Assay

  2001cited by this paper
• Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

  2000cited by this paper
• The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein.

  2000cited by this paper
• Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients.

  1999cited by this paper
• Common variable immunodeficiency: clinical and immunological features of 248 patients.

  1999cited by this paper
• Polyosides (encapsulated bacteria).

  1999cited by this paper
• Characterization of pneumococcal specific antibodies in healthy unvaccinated adults.

  1998cited by this paper
• Evaluation of Previously Assigned Antibody Concentrations in Pneumococcal Polysaccharide Reference Serum 89SF by the Method of Cross-Standardization

  1998cited by this paper
• The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study Group.

  1998cited by this paper
• Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells

  1997cited by this paper
• Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93.

  1996cited by this paper
• Liquid Pasteurization of an Immunoglobulin Preparation without Stabilizer: Effects on its Biological and Biochemical Properties

  1996cited by this paper
• Fragmentation of Therapeutic Human Immunoglobulin Preparations

  1995cited by this paper
• Pneumococcal virulence factors and host immune responses to them

  1995cited by this paper
• Immunoglobulin preparations for intravenous administration

  1994cited by this paper
• Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay.

  1994cited by this paper
• Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications.

  1993cited by this paper
• IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations.

  1992cited by this paper
• Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease.

  1992influential reference
• Intravenous immunoglobulin preparations: a comparative in vitro study of Fc mediated functions.

  1989cited by this paper
• Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin.

  1987cited by this paper
• Infectious complications of the primary immunodeficiencies.

  1986cited by this paper
• X‐Linked Agammaglobulinemia: An Analysis of 96 Patients

  1985cited by this paper
• Correlation of serum immunoglobulin subclass concentrations with antibody responses of children to immunization withHaemophilus influenzae type b polysaccharide-pertussis vaccine

  1985cited by this paper
• Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases.

  1984cited by this paper
• A preparation of modified immune serum globulin (human) suitable for intravenous administration. Further characterization and comparison with pepsin-treated intravenous gamma globulin.

  1984cited by this paper
• The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.

  1983cited by this paper
• Diagnosis and Treatment of Immunodeficiency Diseases

  1981cited by this paper
• Human IgG subclasses in health and disease(A review) Part II

  1980cited by this paper
• Human IgG subclasses in health and disease (A review)Part I

  1980cited by this paper
• Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

  1980cited by this paper
• Quantitative Measurement of “Natural” and Immunization-induced Haemophilus influenzas type b Capsular Polysaccharide Antibodies

  1973influential reference
• Human serum activities against Hemophilus influenzae, type b.

  1972cited by this paper
• Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b.

  1971cited by this paper

• Oropouche Virus: Implications for Transfusion Services

  2025cites this paper
• Serum antibody screening using glycan arrays.

  2024cites this paper
• Sex-based difference in immune responses and efficacy of the pneumococcal conjugate vaccine

  2024cites this paper
• In vitro evaluation of human intravenous immunoglobulin in combination with antimicrobials and human serum against multidrug-resistant isolates of Acinetobacter baumannii

  2023cites this paper
• Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)

  2023cites this paper
• Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET)

  2022cites this paper
• Trough Concentrations of Specific Antibodies in Primary Immunodeficiency Patients Receiving Intravenous Immunoglobulin Replacement Therapy

  2021cites this paper
• Opsonophagocytic Antibodies of Intravenous Immunoglobulin Preparations

  2021cites this paper
• Characterization of antibodies in human immunoglobulin products from different regions worldwide

  2021cites this paper
• Opsonophagocytic Antibodies of Intravenous Immunoglobulin Preparations against Seven Streptococcus agalactiae Serotypes

  2021cites this paper
• Intravenous Immunoglobulin for Overwhelming Postsplenectomy Infection

  2021cites this paper
• Convalescent plasma – this is no time for competition

  2020cites this paper
• Specific Antibody Deficiency in Adult Patients With IgG or IgG Subclass Deficiency

  2020cites this paper
• Neutrophils are required during immunization with the pneumococcal conjugate vaccine for protective antibody responses and host defense against infection

  2020cites this paper
• High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

  2020cites this paper
• Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin

  2019cites this paper
• Clinical and Immunological Features of 78 Adult Patients with Primary Selective IgG Subclass Deficiencies

  2019cites this paper
• Antibody levels to Malassezia pachydermatis and Staphylococcus pseudintermedius in atopic dogs and their relationship with lesion scores.

  2019cites this paper
• Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations

  2019cites this paper
• Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM® and ASCENIV™.

  2019cites this paper
• Measuring quantity and function of pneumococcal antibodies in immunoglobulin products

  2018influential citation
• Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity.

  2018cites this paper
• Antibodies to vaccine antigens in pooled polyclonal human IgG products

  2018influential citation
• 47 – Pneumococcal Polysaccharide Vaccines

  2018cites this paper
• Effective concentration of intravenous immunoglobulin for neutralizing Panton-Valentine leukocidin in human blood.

  2018cites this paper
• New choices for treatment with subcutaneous immunoglobulins.

  2017cites this paper
• Functional antibodies to Haemophilus influenzae type B, Neisseria meningitidis, and Streptococcus pneumoniae contained in intravenous immunoglobulin products

  2017cites this paper
• Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products

  2017cites this paper
• Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection

  2017cites this paper
• New choices for treatment with subcutaneous immunoglobulins.

  2017cites this paper
• RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations

  2017cites this paper
• Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.

  2017cites this paper
• Modifying the Fc Asn297 Glycan of Human IgG2 Subclass for Improved Antibody Therapeutics and Design of Site-Specific Antibody Drug Conjugates

  2017cites this paper
• Selective subnormal IgG3 in 121 adult index patients with frequent or severe bacterial respiratory tract infections.

  2016cites this paper
• Selective Subnormal IgG1 in 54 Adult Index Patients with Frequent or Severe Bacterial Respiratory Tract Infections

  2016cites this paper
• Isotype Diversification against HIV-1 p 24 Associated with Greater Opsonophagocytic IgG Antibody Responses Reactive − Plasmacytoid Dendritic Cell Viremic HIV Controllers Exhibit High

  2015cites this paper
• Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses

  2015cites this paper
• Impaired memory B cell IgG isotype switching and circulating T follicular-helper cell dysfunction in patients with chronic HIV-1 infection

  2015cites this paper
• Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell–Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification

  2015cites this paper
• Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG)

  2015cites this paper
• Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study

  2014cites this paper
• Adequate Patient’s Outcome Achieved with Short Immunoglobulin Replacement Intervals in Severe Antibody Deficiencies

  2014influential citation
• IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations.

  2014cites this paper
• Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe

  2014cites this paper
• Intravenous immunoglobulin suppresses B cell activities via antigen recognition region

  2014cites this paper
• Pneumococcal Antibody Levels in Children With PID Receiving Immunoglobulin

  2014cites this paper
• Intravenous immunoglobulin and Alzheimer’s disease: what now?

  2013cites this paper
• Specific Antibody in IV Immunoglobulin for Postsplenectomy Sepsis

  2013cites this paper
• Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein.

  2013cites this paper
• CD8 co-receptor modifications to enhance T cell immunotherapy

  2013cites this paper
• Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology.

  2012cites this paper
• P4-mediated antibody therapy in an acute model of invasive pneumococcal disease.

  2012cites this paper
• IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation

  2011cites this paper
• Monomeric and Dimeric IgG Fractions Show Differential Reactivity Against Pathogen‐Derived Antigens

  2011cites this paper
• Complement-mediated bacteriolysis after binding of specific antibodies to drug-resistant Pseudomonas aeruginosa: morphological changes observed by using a field emission scanning electron microscope

  2010cites this paper
• CHAPTER 17 – Intravenous Immune Serum Globulin (IVIG) Therapy in Patients with Antibody Immune Deficiency

  2010cites this paper
• IVIg contains a broad repertoire of anti-carbohydrate antibodies that is not restricted to the IgG2 subclass

  2009cites this paper
• Evaluation of a Novel Therapeutic Approach to Treating Severe Pneumococcal Infection Using a Mouse Model

  2009cites this paper
• Role of antibodies and T cells in pigeon fanciers' lung

  2009cites this paper
• Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency

  2009cites this paper
• Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass.

  2009cites this paper
• Immunodeficiencies

  2009cites this paper
• Pneumococcal polysaccharide vaccines

  2008cites this paper
• Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant pseudomonas aeruginosa.

  2008cites this paper
• Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations.

  2008cites this paper
• Serotype-Specific and Age-Dependent Generation of Pneumococcal Polysaccharide-Specific Memory B-Cell and Antibody Responses to Immunization with a Pneumococcal Conjugate Vaccine

  2007cites this paper
• Quantitative measurements of Hemophilus influenzae type b capsular polysaccharide antibodies in Japanese children

  2007cites this paper
• Antibody Responses to Immunization with Polysaccharide-specific Memory B-cell and Generation of Pneumococcal Serotype-specific and Age-dependent

  2007cites this paper
• Measles-virus-neutralizing antibodies in intravenous immunoglobulins.

  2006cites this paper
• Prevalência e tipagem molecular da cápsula de Haemophilus influenzae isolados da nasofaringe de crianças pós-introdução da vacina Hib-conjugada no município de Goiânia

  2005cites this paper
• Intravenous immunoglobulin in immunodeficiency states

  2005cites this paper